SCHEMBL17765409

SCHEMBL17765409

Clc1ccc2c3c(ccc2c1)-c1ccccc1C3c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.43
ESR2 Q92731 2/20 0.43
CYP2A6 P11509 1/20 0.37
RAB9A P51151 1/20 0.35
ALOX12 P18054 1/20 0.34
DPP4 P27487 2/20 0.33
S100A4 P26447 1/20 0.33
GPR3 P46089 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
HTR2B P41595 1/20 0.32
ACHE P22303 2/20 0.32
TRPM4 Q8TD43 2/20 0.32
TRPM5 Q9NZQ8 2/20 0.32
EDNRB P24530 1/20 0.30
EDNRA P25101 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17765469 0.83 ESR1 (0.43) ESR1ESR2CYP2A6GPR3LMNA
SCHEMBL8966049 0.82 ESR1 (0.41) ESR1ESR2CYP2A6LMNATP53
SCHEMBL17765458 0.80 ESR1 (0.48) ESR1ESR2CYP2A6RAB9ADPP4
SCHEMBL17765402 0.76 DPP4 (0.45) ESR1ESR2RAB9ADPP4
SCHEMBL17765452 0.75 ESR1 (0.38) ESR1ESR2CYP2A6GPR3LMNA
SCHEMBL17773356 0.74 ACHE (0.41) ESR1ESR2RAB9ADPP4LMNA
SCHEMBL8965802 0.71 MEN1 (0.44) ESR1ESR2CYP2A6TP53CYP1A2
SCHEMBL27614949 0.71 MAPK1 (0.40) ESR1ESR2LMNATP53CYP1A2
SCHEMBL8966091 0.70 ESR1 (0.57) ESR1ESR2CYP2A6RAB9ATP53
SCHEMBL21732782 0.70 EDNRB (0.44) RAB9AALOX12LMNATP53CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676679-B2 Traceless directing groups in radical cascades: from oligoalkynes to fused helicenes without tethered initators The Florida State University Research Foundation, Inc. (US) 2017-06-13 US disclosed
US-9676679-B2 Traceless directing groups in radical cascades: from oligoalkynes to fused helicenes without tethered initators The Florida State University Research Foundation, Inc. (US) 2017-06-13 US disclosed
US-9676679-B2 Traceless directing groups in radical cascades: from oligoalkynes to fused helicenes without tethered initators The Florida State University Research Foundation, Inc. (US) 2017-06-13 US disclosed
US-20160145276-A1 TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS The Florida State University Research Foundation, Inc 2016-05-26 US disclosed
US-20160145276-A1 TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS The Florida State University Research Foundation, Inc 2016-05-26 US disclosed
US-20160145276-A1 TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS The Florida State University Research Foundation, Inc 2016-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145276-A1 TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS OR51E2, OR10J3, ORC3 ESR1 2073/4885ESR2 1308/4885CYP2A6 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.